Mainie Pramod
Research Fellow, Hammersmith Hospital, Department of Haematology, London W12 0HS, United Kingdom.
Early Hum Dev. 2008 Aug;84(8):525-32. doi: 10.1016/j.earlhumdev.2008.06.002. Epub 2008 Jul 23.
Since it was first cloned in 1985, the therapeutic potential of recombinant human erythropoietin in the neonatal hyporegenerative anaemias has been studied-the anaemia of prematurity and haemolytic disease of the newborn. Between 60% and 100% of preterm infants are transfused before three weeks of age, a large proportion receiving more than one transfusion. Blood transfusions are currently also the mainstay of treatment for the hyporegenerative anaemia encountered in neonates with Rhesus disease. Sometimes the situation is complicated by the religious beliefs of the parents. Blood transfusions are associated with numerous risks, from transmission of infection to local injury, and in an effort to minimize these risks Neonatologists have looked to recombinant erythropoietin. Despite an extensive number of studies, there is as yet no clear consensus as to whether the use of recombinant erythropoietin in Neonatal medicine minimizes the need for blood transfusions without risk to the neonate. In this article we review the evidence for and against the use of recombinant erythropoietin in Neonatal medicine.
自1985年首次克隆以来，重组人促红细胞生成素在新生儿低再生性贫血（早产儿贫血和新生儿溶血病）中的治疗潜力已得到研究。60%至100%的早产儿在3周龄前接受输血，很大一部分接受不止一次输血。输血目前也是患有恒河猴病的新生儿中遇到的低再生性贫血的主要治疗方法。有时情况会因父母的宗教信仰而变得复杂。输血伴随着众多风险，从感染传播到局部损伤，为了尽量减少这些风险，新生儿科医生将目光投向了重组促红细胞生成素。尽管进行了大量研究，但对于在新生儿医学中使用重组促红细胞生成素是否能在不危及新生儿的情况下减少输血需求，目前尚无明确共识。在本文中，我们回顾了支持和反对在新生儿医学中使用重组促红细胞生成素的证据。
